Stifel analyst James Condulis reiterated a Buy rating and $136.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented: "Ipsen ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE